Robert McNeil

ACEA Biosciences, Inc. develops bio-sensor platform based on microelectronic technologies. The firm pioneers in development and commercialization of innovative cell analysis instrumentation for life sciences, and is also engaged in drug discovery and pharmaceutical development. Its xCELLigence impedance-based, label-free, real-time cell analysis systems and NovoCyte benchtop flow cytometers are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. The company was founded in 2002 and is headquartered in San Diego, CA.

Kadmus Pharmaceuticals, Inc. manufactures and sells biopharmaceutical products. It develops and commercializes proprietary molecules targeting critical pathways contributing to pain, disorders of the nervous system, and other unmet medical needs. The firm also performs formulation, pre-clinical development and also oversees the manufacturing, preclinical toxicology, and clinical development of candidate drugs via a key vendor network. Kadmus Pharmaceuticals was founded in 1998 and is headquartered in Irvine, CA.

Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA.

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

Part of Sun International Ltd., San Francisco Investment SA operates casinos. The company is based in San Francisco De Mostazal, Chile. San Francisco Investment was acquired by Sun International Ltd. on December 01, 2014 for $113.98 million.

NRB, Inc. operates as a modular construction company which designs and manufactures modular buildings. The company was founded by Jean Doreen McNeil and Robert George McNeil in 1979 and is headquartered in Grimsby, Canada.

Therillia Development Co., Inc. operates as a portfolio company of Sanderling Ventures. It develops novel drug candidates of interest to Sanderling and other venture capital investors from preclinical to clinical proof of concept. The company is headquartered in Montreal, Canada.

DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.

Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada.